Cogimpa, a Webionz.com project by Fidel Olivieri Logo
    • Uitgebreid zoeken
  • Gast
    • Inloggen
    • Registereren
    • Nachtstand
emmaverghise Cover Image
User Image
Sleep naar de juiste positie
emmaverghise Profile Picture
emmaverghise

@emmaverghise

  • Tijdlijn
  • Groepen
  • Respects
  • Volgend
  • Volgers
  • Foto's
  • Video's
  • Rollen
emmaverghise profile picture emmaverghise profile picture
emmaverghise
13 uur

The U.S. nutrigenomics market reached USD 185.06 million in 2024 and is forecast to grow at a CAGR of 17.6% through 2034, reflecting the field’s entrenched position in mainstream healthcare, wellness, and preventative medicine. While the United States remains the dominant force globally, countries such as China, Germany, and South Korea are playing pivotal roles in shaping the industry’s trajectory. National policy impact, market share concentration, R&D leadership, and strategic positioning are increasingly influential in determining corporate success amid rising global competition and shifting geopolitical dynamics.
In the U.S., federal agencies such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) continue to drive regulatory frameworks that support the scientific validation and clinical adoption of nutrigenomic testing. The Bipartisan Infrastructure Law and recent updates to the 21st Century Cures Act have catalyzed new capital investments from major players like Quest Diagnostics, Thermo Fisher Scientific, and Nutrigenomix, who are expanding testing capacities and integrating AI-based interpretation tools. Strategic acquisitions—such as LabCorp’s acquisition of Personalized Nutrition and ZOE’s partnership with King’s College London—are consolidating market share and reinforcing the dominance of established players in both research and commercialization phases.
China has emerged as a formidable contender, with state-backed programs like the Precision Medicine Initiative and Made in China 2025 strategy supporting domestic innovation in nutrigenomics. BGI Genomics and Wuxi AppTec are aggressively scaling up their capabilities in population genetics and bioinformatics, often partnering with Western diagnostics firms to access global markets. Trade policies and export controls, however, remain a source of uncertainty, prompting some multinational corporations to diversify their supply chains and establish satellite labs in Southeast Asia.
Read More @ https://www.polarismarketresea....rch.com/industry-ana
Germany stands out for its methodical approach to nutrigenomics, characterized by strong collaboration between academia, industry, and regulatory bodies. The Max Planck Institute and University Hospital Heidelberg play instrumental roles in translating basic research into commercial applications, while companies like Qiagen and Eurofins Genomics are investing heavily in next-generation sequencing platforms and proprietary SNP databases. The country’s emphasis on quality control and process standardization makes it a preferred location for setting up centralized testing laboratories catering to European and global clients.
Corporate strategies among top-tier players are increasingly centered around geographic expansion, vertical integration, and technology leadership. Major firms are not only acquiring boutique analytics shops but also building internal capabilities in machine learning, digital therapeutics, and remote patient monitoring to enhance system reliability and customer satisfaction. Market share concentration remains moderate, with the top five companies accounting for approximately 57% of total revenue, although niche players specializing in specific disease pathways or ethnic populations are gaining traction in targeted therapeutic areas.
R&D leadership is concentrated among a few dominant players who invest heavily in multi-omics integration, population-specific biomarkers, and AI-enhanced dietary modeling designed to improve clinical relevance and scalability. Strategic positioning is also influenced by patent portfolios and participation in international consortia, which provide leverage in licensing negotiations and market access discussions. As the nutrigenomics market matures, companies that align their innovation pipelines with macroeconomic shifts and policy imperatives will be best positioned to capitalize on the long-term tailwinds shaping the future of personalized nutrition.
Dominant Players by Market Share:
• Nutrigenomix Inc.
• DNAfit Ltd.
• Pathway Genomics Corporation
• Quest Diagnostics Incorporated
• BGI Genomics Co., Ltd.
• Thermo Fisher Scientific Inc.
• MyDNA Life Inc.
• ZOE Inc.
More Trending Latest Reports By Polaris Market Research:
Cladding Systems Market
Robot Charging Station Market
Ultrasonic Air Bubble Detectors Market
Healthcare It Market
Tiki Torch Market
Healthy Snacks Market
Lipid Regulators Market
Superfoods Market
Electric Kick Scooters Market

U.S. Nutrigenomics Market Size, Value & Share Analysis [2034]
www.polarismarketresearch.com

U.S. Nutrigenomics Market Size, Value & Share Analysis [2034]

U.S. Nutrigenomics Market in terms of revenue was estimated to be worth USD 185.06 million in 2024 and exhibiting a CAGR of 17.6% by 2034
Respect!
Kommentar
Delen
emmaverghise profile picture emmaverghise profile picture
emmaverghise Heeft haar profielfoto gewijzigd
13 uur

image
Respect!
Kommentar
Delen
 Laad meer berichten
    info
    • Vrouw
    • posts 2
    Albums 
    (0)
    Volgend 
    (0)
    Volgers 
    (2)
    Respects 
    (0)
    Groepen 
    (0)

© 2025 Cogimpa, a Webionz.com project by Fidel Olivieri

Language

  • About
  • Directory
  • blog
  • Contact Us
  • Developers
  • Meer
    • Privacy Policy
    • Terms of Use
    • Vraag een terugbetaling

Unfriend

Weet je zeker dat je wilt ontvrienden?

Rapporteer deze gebruiker

Belangrijk!

Weet u zeker dat u dit lid van uw familie wilt verwijderen?

Je hebt geplooid Emmaverghise

Nieuw lid is succesvol toegevoegd aan je familielijst!

Snijd je avatar bij

avatar

© 2025 Cogimpa, a Webionz.com project by Fidel Olivieri

  • Home
  • About
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Vraag een terugbetaling
  • blog
  • Developers
  • Language

© 2025 Cogimpa, a Webionz.com project by Fidel Olivieri

  • Home
  • About
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Vraag een terugbetaling
  • blog
  • Developers
  • Language

Reactie succesvol gerapporteerd.

Post is succesvol toegevoegd aan je tijdlijn!

U heeft uw limiet van 5000 vrienden bereikt!

Bestandsgrootte fout: Het bestand overschrijdt de limiet toegestaan ​​(92 MB) en kan niet worden geüpload.

Je video wordt verwerkt, we laten je weten wanneer het klaar is om te bekijken.

Kan een bestand niet uploaden: dit bestandstype wordt niet ondersteund.

We hebben een aantal inhoud voor volwassenen gevonden in de afbeelding die je hebt geüpload. Daarom hebben we je uploadproces geweigerd.

Deel bericht over een groep

Deel naar een pagina

Deel met gebruiker

Je bericht is verzonden. We zullen je inhoud binnenkort beoordelen.

Om afbeeldingen, videos en audiobestanden te uploaden, moet je upgraden naar pro-lid. Upgraden naar Pro

Aanbieding bewerken

0%

Voeg tier toe








Selecteer een afbeelding
Verwijder je tier
Weet je zeker dat je deze tier wilt verwijderen?

beoordelingen

Om uw inhoud en berichten te verkopen, begint u met het maken van een paar pakketten. Inkomsten genereren

Betaal per portemonnee

Pakket toevoegen

Verwijder uw adres

Weet je zeker dat je dit adres wilt verwijderen?

Verwijder uw pakket voor het genereren van inkomsten

Weet u zeker dat u dit pakket wilt verwijderen?

Uitschrijven

Weet u zeker dat u zich wilt afmelden voor deze gebruiker? Houd er rekening mee dat u geen van hun inhoud waarmee inkomsten worden gegenereerd, kunt bekijken.

Betalingswaarschuwing

Je staat op het punt om de items te kopen, wil je doorgaan?
Vraag een terugbetaling

Language

  • Arabic
  • Bengali
  • Chinese
  • Croatian
  • Danish
  • Dutch
  • English
  • Filipino
  • French
  • German
  • Hebrew
  • Hindi
  • Indonesian
  • Italian
  • Japanese
  • Korean
  • Persian
  • Portuguese
  • Russian
  • Spanish
  • Swedish
  • Turkish
  • Urdu
  • Vietnamese